

# VU Research Portal

## Towards molecular imaging for personalized therapy of patients with colorectal cancer liver metastasis

Goos, J.A.C.M.

2015

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Goos, J. A. C. M. (2015). *Towards molecular imaging for personalized therapy of patients with colorectal cancer liver metastasis*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## Summary

Approximately half of the patients suffering from cancer in colon or rectum dies as a consequence of dissemination to other organs, which often occurs to the liver. Only 36-58% of the patients treated with resective surgery of the colorectal cancer liver metastases (CRCLM) survives longer than five years after resection. Biological markers with added prognostic value to the standard clinical prognostic parameters may be visualized using molecular imaging techniques, such as positron emission tomography (PET). We focused on the identification of proteins that could be used as prognostic biological markers and for one of these we developed a novel tracer for PET imaging.

In tissue samples of 507 patients with CRCLM, we identified SLC2A1, VEGFA, EGFR, PTGS2 and AURKA as strong and independent prognostic biological markers. Furthermore, we demonstrated that the combination of AURKA, PTGS2 and MMP9 was superior to the standard clinical prognostic parameters in predicting survival. Considering the prognostic value of AURKA, we labeled a specific AURKA inhibitor, i.e. alisertib, with radio-isotopes and demonstrated that this PET tracer was capable of visualizing high AURKA levels in preclinical models.

This research provides another small step towards obtaining a complete overview of CRCLM biology. It is our vision that personalization of cancer treatment based on the biological profile of the CRCLM, in combination with the clinical profile, will improve survival of patients with CRCLM.